Valeria Azcarate-Rodriguez

Valeria Azcarate-Rodriguez

Auto-generated profile, based on publicly available information

Valeria Azcarate-Rodriguez

Facultad de ciencias de la salud Universidad Icesi Cali Colombia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2025 in Global Heart
Verified
Journal Article
Open access
PDF file
ASAlex David Sotomayor-Julio
Alex David Sotomayor-Julio
SSSebastián Seni-Molina
Sebastián Seni-Molina
JGJuliana María Gutiérrez-Posso
Juliana María Gutiérrez-Posso
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
VAValeria Azcárate-Rodríguez
Valeria Azcárate-Rodríguez
OGOn Behalf of AMERICCAASS Research Group
On Behalf of AMERICCAASS Research Group
Introduction: Heart failure (HF) is a leading cause of hospitalization and mortality worldwide, emphasizing the critical role of optimal medical therapy (OMT) in improving patient outcomes. Despite extensive research, most scientific evidence regarding HF is gathered and studied in developed countries, leaving substantial knowledge gaps regarding HF in Latin America and the Caribbean. Objective: To characterize the sociodemographic and clinical profiles of HF patients and to assess their adherence to OMT in the Americas. Methods: The AMERICCAASS Registry is a prospective, observational, multicenter study, including patients aged 18 and older, both hospitalized and ambulatory, and diagnosed with HF. Sociodemographic and clinical data were collected from the first 2,500 patients to characterize the study population. Adherence to OMT was subsequently evaluated according to left ventricular ejection fraction (LVEF). Results: Among the 2,500 patients in the study, 36% were hospitalized and 64% were ambulatory. The median ages of the patients were 66.9 (hospitalized) and 66.3 years (ambulatory). Males made up 60.8% of hospitalized and 59.3% of ambulatory patients. The majority had HF with reduced LVEF (≤40%): 60.7% for hospitalized and 58.5% for ambulatory. The New York Heart Association (NYHA) functional class II predominated among ambulatory patients (67.9%), while NYHA functional class III predominated among hospitalized patients (46.6%). Only 21% of patients with reduced LVEF were receiving quadruple therapy, whereas 12.3% of patients with mildly reduced LVEF (41–49%) were on this treatment. Conclusion: The findings demonstrate that the sociodemographic and clinical profiles of HF patients in the Americas are broadly consistent with international reports. However, the low use of OMT observed in this population underscores gaps in adherence to current guidelines. These results highlight the need for targeted strategies to improve pharmacological treatment adherence to optimize health outcomes in this region.

5 May 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
JAJuan Pablo Arango‐Ibanez
Juan Pablo Arango‐Ibanez
SSSebastián Seni‐Molina
Sebastián Seni‐Molina
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
VAValeria Azcárate‐Rodríguez
Valeria Azcárate‐Rodríguez
AVAndrea Valencia‐Orozco
Andrea Valencia‐Orozco
SMSebastian Seni Molina
Sebastian Seni Molina
Background: Acute heart failure (HF) frequently coexists with multimorbidity. Comorbidity clusters have been associated with distinct clinical outcomes, but data from the Americas remain limited. We aimed to identify comorbidity clusters in patients with acute HF and assess their association with in‐hospital outcomes. Methods: This cohort study applied latent class analysis to patients from the AMERICCAASS Registry (Registro Americano de Insuficiencia Cardiaca Ambulatoria o Agudamente descompensada). Adjusted Poisson regression assessed in‐hospital mortality and intensive care unit (ICU) admission, and multivariable analysis identified independent predictors of ICU admission. Results: Among 1638 patients, 60.6% were men and the median age was 67.2 years. Hypertension (69.4%), smoking (40.3%), and coronary artery disease (33.8%) were common comorbidities. Cluster 1 (Young, n=828) included the youngest patients (median age 63.2 years) with the fewest comorbidities. Cluster 2 (Cardio‐Kidney‐Metabolic, n=512) represented the oldest group (median age 71.8 years) with the highest median body mass index (27.7 kg/m 2 ), the greatest proportion of HF with mildly reduced or preserved ejection fraction (44.7%), and a high comorbidity burden. Cluster 3 (“Ischemic,” n=298) was characterized by older patients (median age 70.2 years) with an exceptionally high prevalence of coronary artery disease (96.3%) and the greatest proportion of HF with reduced ejection fraction (61.4%). ICU admission risk was higher in Cluster 2 (adjusted risk ratio [aRR], 1.15 [95% CI, 1.03–1.27]; P =0.009) and Cluster 3 (aRR, 1.25 [95% CI, 1.12–1.39]; P <0.001), compared with Cluster 1. Severe valvular insufficiency, peripheral artery disease, dyslipidemia, cancer, acute coronary syndrome, anemia, and cardiogenic shock were associated with higher ICU admission risk. Conclusions: Patients with acute HF in the Americas exhibit distinct comorbidity patterns associated with different clinical profiles and ICU admission rates, which may inform risk stratification and management strategies. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05295641.

Verified
Journal Article
Open access
PDF file
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
MEManuela Escalante
Manuela Escalante
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
VAValeria Azcárate-Rodriguez
Valeria Azcárate-Rodriguez
Juan David Peláez-MartínezJuan David Peláez-Martínez
Juan David Peláez-Martínez
JMJORGE DANIEL SIERRA -LARA MARTINEZ
JORGE DANIEL SIERRA -LARA MARTINEZ
Background: The COVID-19 pandemic has highlighted a correlation between cardiac complications and elevated cardiac biomarkers, which are linked to poorer clinical outcomes. Objective: This study aims to determine the clinical impact of cardiac biomarkers in COVID-19 patients in Latin America. Subjects and methods: The CARDIO COVID 19-20 Registry is a multicenter observational study across 44 hospitals in Latin America and the Caribbean. It included hospitalized COVID-19 patients (n = 476) who underwent troponin, natriuretic peptide, and D-dimer tests. Patients were grouped based on the number of positive biomarkers. Results: Among the 476 patients tested, 139 had one positive biomarker (Group C), 190 had two (Group B), 118 had three (Group A), and 29 had none (Group D). A directly proportional relationship was observed between the number of positive biomarkers and the incidence of decompensated heart failure. Similarly, there was a proportional relationship between the number of positive biomarkers and increased mortality. In Group B, patients with elevated troponin and natriuretic peptide and those with elevated troponin and D-dimer had 1.4 and 1.5 times higher mortality, respectively, than those with elevated natriuretic peptide and D-dimer. Conclusions: In Latin American COVID-19 patients, a higher number of positive cardiac biomarkers is associated with increased cardiovascular complications and mortality. These findings suggest that cardiac biomarkers should be utilized to guide acute-phase treatment strategies.

14 January 2026 in Global Heart
Verified
Journal Article
Open access
JLJuan David Lopez
Juan David Lopez
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
Alejandro Toro-PedrozaAlejandro Toro-Pedroza
Alejandro Toro-Pedroza
JAJuan Pablo Arango-Ibanez
Juan Pablo Arango-Ibanez
VAValeria Azcarate-Rodriguez
Valeria Azcarate-Rodriguez
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
Background: Heart transplantation (HT) remains the definitive treatment for advanced heart failure that is refractory to both medical and invasive therapies. Although global registries offer extensive data on survival outcomes, there is a relative paucity of information regarding HT outcomes in Latin America (LATAM), particularly in Colombia. Methods: This study analyzed adult patients who underwent HT between 1995 and 2024, using data obtained from an institutional HT registry (RETRAC) in Cali, Colombia. Survival outcomes were evaluated using Kaplan–Meier curves and Cox proportional hazards models. Results: We included 260 patients who underwent HT in this 29-year cohort from a LATAM country. The median age at transplantation was 51 years, and 77.7% were male. The primary etiologies were idiopathic/dilated cardiomyopathy (IDC) (41.3%), ischemic cardiomyopathy (IC) (27.0%), and valvular heart disease (VHC) (9.7%). The most prevalent comorbidities were hypertension (HTN) (48.3%), diabetes mellitus (DM) (18.9%), and chronic kidney disease (CKD) (13.1%). The overall median survival following HT was 7.4 years. One-year survival was 74.6% (n = 194), five-year survival was 56.9% (n = 147), and ten-year survival was 46.9% (n = 122). Survival differed significantly by age and sex, with patients aged <40 years demonstrating the highest median survival (8.4 years) and those aged ≥60 years the lowest (2.2 years) (p = 0.038). The 40- to 49-year age group exhibited the most pronounced reduction in survival; however, this effect was attenuated after adjustment. Among patients under 40 years, females had significantly higher mortality compared to males (p = 0.0078), with younger males exhibiting better survival. Additionally, patients transplanted between 2016 and 2020 had higher survival rates. CKD was identified as a significant independent risk factor for increased mortality (hazard ratio (HR) = 1.79; 95% CI: 1.15–2.79; p = 0.01). Conclusions: HT patients in Colombia exhibit demographic and clinical profiles comparable to global cohorts; however, they demonstrate lower survival rates and poorer clinical outcomes compared to international registries, such as the International Society for Heart and Lung Transplantation registry. Nonetheless, clinical outcomes are more favorable than those reported in other studies from the LATAM region. CKD emerged as a significant independent predictor of mortality. These findings highlight the need for region-specific strategies aimed at improving HT outcomes in LATAM.

8 January 2026 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
SSSebastián Seni-Molina
Sebastián Seni-Molina
AMArturo D. Mora
Arturo D. Mora
VAValeria Azcarate-Rodriguez
Valeria Azcarate-Rodriguez
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
HLHoover León-Giraldo
Hoover León-Giraldo
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
Thromboembolic disorders remain a leading cause of morbidity and mortality. Although anticoagulation therapy (AT) has reshaped practice worldwide, real-wor

1 July 2026 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
MGMiller Giraldo‐Sandoval
Miller Giraldo‐Sandoval
FGFernando Andrés Guerrero‐Pinedo
Fernando Andrés Guerrero‐Pinedo
ÁHÁngela María Herrera‐Peña
Ángela María Herrera‐Peña
JAJuan David Agrado‐Torres
Juan David Agrado‐Torres
JCJulián Mauricio Cortés‐Colorado
Julián Mauricio Cortés‐Colorado
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct subtype of pulmonary hypertension arising from persistent major pulmonary artery obstruction after pulmonary embolism. Pulmonary endarterectomy (PEA) remains the standard of care, but up to 40% of patients in European and US registries are inoperable; balloon pulmonary angioplasty (BPA) has emerged as a more accessible interventional modality for suitable patients. This retrospective single‐center cohort study evaluated functional improvement, hemodynamic response, and mortality in patients with CTEPH ineligible for PEA who underwent BPA at a Colombian institution (May 2022–October 2025). Risk was stratified using COMPERA 2.0. The primary outcome was improvement of at least one New York Heart Association (NYHA) functional class; secondary outcomes were change in mean pulmonary arterial pressure (mPAP) and all‐cause mortality during follow‐up. Of 33 patients (median age 63 years; 70% female), 5 (15.1%) were high risk at baseline, 16 (48.4%) intermediate‐high, 10 (30.3%) intermediate‐low, and 2 (6%) low risk. After BPA, 19 patients (58%) improved NYHA class (95% CI, 39.2%–74.5%), and mPAP fell from 60 (IQR 50–68) to 40 mmHg (IQR 37–48) after a median of three sessions (IQR 2–4) (mean paired reduction 14.05 mmHg, 95% credible interval 9.81–18.07; Hedges’ g = 1.22, 95% CI 0.77–1.66). Two deaths (6.0%) occurred, both in high‐risk patients. BPA improved NYHA class and pulmonary hemodynamics in severe, inoperable CTEPH, with a low complication rate despite advanced baseline disease. COMPERA 2.0 stratified baseline severity but did not predict the magnitude of hemodynamic response to BPA, consistent with the mechanical nature of the disease.